1 Original Article

2

3 **Increased adiposity is protective for breast and prostate cancer: a Mendelian**
 4 **randomisation study using up to 132,413 breast cancer cases and 85,907 prostate**
 5 **cancer cases**

6

7 ¹H. A. Amin, ¹P. Kaewsri, ¹A. M. Yiorkas, ¹H. Cooke, ¹A. I. Blakemore, and ¹F. Drenos

8

9 ¹Department of Life Sciences, College of Health and Life Sciences, Brunel University
 10 London, Uxbridge, United Kingdom

11

12 Corresponding Author:

13

14 Dr Fotios Drenos

15

16 Department of Life Sciences
 17 College of Health and Life Sciences
 18 Brunel University London
 19 Kingston Lane
 20 Uxbridge
 21 Middlesex
 22 UB8 3PH
 23 United Kingdom

24

25 +44 (0)1895 266951

26 Fotios.Drenos@brunel.ac.uk

27

28

29 **ABSTRACT**

30

31 Background

32 Breast and prostate cancer are the first and second most common types of cancer in
33 women and men, respectively. A recent campaign by Cancer Research UK emphasised
34 obesity as being a causal risk factor for cancer, although previously published evidence
35 is heterogenous. We aimed to explore the causal effect of adiposity on breast and
36 prostate cancer risk in the UK Biobank (UKB), a large prospective cohort study, and
37 published data.

38

39 Methods

40 We used Mendelian randomisation (MR) to assess the causal effect of body mass index
41 (BMI), body fat percentage (BFP), waist circumference (WC), hip circumference (HC),
42 and waist-to-hip ratio (WHR) on breast and prostate cancer risk.

43

44 Results

45 We obtained estimates (odds ratios, OR, per SD unit increase) of the causal effect of the
46 adiposity measures on breast and prostate cancer risk. BMI and HC decrease the risk of
47 breast cancer (OR 0.776 [95% CIs 0.661-0.91] and OR 0.781 [95% CIs 0.649-0.94],
48 respectively). WC, BFP, and BMI decrease the risk of prostate cancer (OR 0.602 [95% CIs
49 0.439-0.825], OR 0.629 [95% CIs 0.414-0.956], and OR 0.695 [95% CIs 0.553-0.874],
50 respectively). The protective effect of adiposity on prostate cancer risk is enhanced in
51 men who are exposed to potentially hazardous substances at work, and the association
52 between BMI and breast cancer is confounded by variables associated with general
53 health.

54

55 Conclusions

56 In conclusion, increasing adiposity is causally protective for breast and prostate cancer
57 and the effects in prostate cancer may, at least partly, be due to the safe storage of
58 chemicals in adipose cells. It is necessary to explore the mechanisms through which
59 adiposity may protect against or be a risk factor for cancer, to identify how the latter
60 can be minimised without sacrificing the former, and to base public health campaigns
61 around sound evidence.

62

63 **KEYWORDS**

64

65 Obesity; Breast cancer; Prostate cancer; Mendelian randomization; Persistent organic
66 pollutants.

67

68 HIGHLIGHTS

69

- 70 • Previously published evidence regarding the effect of adiposity on prostate and
- 71 breast cancer risk is heterogenous
- 72 • Increasing BMI and hip circumference decrease the risk of breast cancer in
- 73 women
- 74 • Increasing waist circumference, body fat percentage, and BMI decrease the risk
- 75 of prostate cancer
- 76 • The protective effect of adiposity on prostate cancer is stronger in men who are
- 77 exposed to carcinogens at work
- 78 • Public health campaigns need to target the negative aspects of adiposity whilst
- 79 preserving the positive aspects

80

81

82 INTRODUCTION

83

84 Breast and prostate cancer are the most common and second most common types of
85 cancer diagnosed worldwide in men and women, respectively.¹ In 2010, the combined
86 cost of breast and prostate cancer to the NHS was £664 million.² The number of cases
87 are expected to rapidly increase and, by 2040, are estimated to be 20.2% higher for
88 breast cancer and 38.5% higher for prostate cancer in comparison to 2018.¹ Both cancer
89 types are preventable in many cases, making robust identification of their modifiable
90 risk factors important.

91

92 A recent campaign by Cancer Research UK³ has emphasised obesity as being a causal
93 risk factor for cancer comparable to smoking. It has been proposed that the metabolic
94 environment in obese people is conducive to oncogenic transformation.⁴ However,
95 previously published evidence on the relationship between adiposity and breast and
96 prostate cancer does not consistently support this view.⁵⁻⁷ It has been suggested that
97 adiposity is a risk factor for breast cancer in post-menopausal women,⁸ but not in pre-
98 menopausal women.⁹ The effect of BMI on prostate cancer risk is reported to depend
99 upon the aggressiveness of the tumour.¹⁰

100

101 Assessment of what exposures are causal is not trivial: “correlation is not causation”.
102 The vast majority of studies carried out to examine the impact of adiposity on breast
103 and prostate cancer risk are observational and may be susceptible to confounding.
104 Mendelian randomisation (MR) is a method that uses genetic variants associated with
105 an exposure of interest, but not with any confounders, to assess the causal effect of the
106 genetically predicted exposure on an outcome. In order for the method to provide
107 reliable estimates of the causal effect, it is also assumed that the chosen instruments
108 are not related to the outcome of interest independently of the exposure (this is known
109 as the “exclusion restriction” assumption).

110

111 With this work, we aim to explore the causal effect of adiposity on breast and prostate
112 cancer risk in the UK Biobank (UKB), a large prospective cohort study, and published
113 data.¹¹⁻¹⁵ We also aim to use the rich phenotype data collected as part of the UKB study
114 to identify variables, if any, that may explain the observed relationship between
115 adiposity and breast and prostate cancer risk.

116

117 **SUBJECTS AND METHODS**

118

119 Population and Study Design

120

121 The UK Biobank (UKB) is a large prospective cohort study including information and
122 biological samples for approximately 500,000 individuals, recruited between 2006 and
123 2011. The 22 UKB assessment centres throughout England, Wales and Scotland,
124 collected baseline data from the participants in the form of questionnaires, physical and
125 cognitive tests and blood and urine samples.¹⁶ The age range of the participants at the
126 time of enrolment in the study was between 40 and 69 years of age, with a mean age of
127 56.5 years. Males represent 45.6% of the sample. The use of the data for this project
128 was approved by the UKB (application 44566).

129

130 Genotyping

131

132 488,377 individuals had been genotyped for up to 812,428 variants using DNA extracted
133 from blood samples on either the UKB Axiom array (438,427 participants) or the UK
134 BiLEVE Axiom array (49,950 participants). Variants that did not pass standard quality
135 control checks were excluded.¹⁷ These included tests for the presence batch effects,
136 plate effects, sex effects and array effects, as well as any departures from Hardy-
137 Weinberg Equilibrium using a p-value threshold of 10^{-12} . Variants with a minor allele
138 frequency of <0.01 were also excluded. For imputed variants, all variants with an INFO
139 score of <0.8 were excluded from the analysis.

140

141 Sample genotyping quality control metrics were provided by UKB.¹⁷ Samples were
142 excluded from the analysis if they were outliers for missingness and/or PC-corrected
143 heterozygosity and/or if they had any sex chromosome aneuploidies as well as if the
144 genetically inferred sex differed from the reported sex. Samples which did not have a
145 genetically determined White British ancestry were also excluded. A list of related
146 individuals was also provided by UKB and one individual from each related pair was
147 excluded at random.

148

149 Phenotypes

150

151 We used data collected at baseline for body mass index (BMI, UKB field 21001), body fat
152 percentage (BFP, UKB field 23099) from bio-impedance, waist circumference (WC, UKB
153 field 48) and hip circumference (HC, UKB field 49). We calculated waist-to-hip ratio
154 (WHR) by dividing WC by HC. The variables were standardised to a mean of 0 and a
155 variance of 1.

156

157 We used cancer diagnoses information from the 1970s onward obtained from linkage to
158 national cancer registries and health records (see
159 <http://biobank.ndph.ox.ac.uk/showcase/showcase/docs/CancerLinkage.pdf>). Breast
160 cancer cases are defined as females who have an ICD-10 code C50 recorded at least
161 once (UKB field 40006). Prostate cancer cases are defined as males who have an ICD-10
162 code C61 recorded at least once (UKB field 40006). Females who have an ICD-10 code
163 D05, for in situ carcinoma of the breast, without a C50 breast cancer entry were
164 removed from the sample. Similarly, males with an ICD-10 code D075, for carcinoma in
165 situ of prostate, without a C61 prostate cancer diagnosis were also removed from the
166 sample.

167

168 Menopause information for females was obtained through the reported age of
169 menopause information collected (UKB field 3581). This information was compared to
170 the age of first breast cancer diagnosis to identify the pre- and post-menopausal cases.
171 For women who did not have breast cancer, we used their menopause status at
172 baseline to stratify them into pre- and post-menopausal.

173

174 Exposure to chemicals was based on occupation exposure information. A participant
175 was considered to have been exposed to chemicals frequently if they answered “Often”
176 and/or “Sometimes” at least once for any of the following UKB fields: 22609 (Workplace
177 very dusty); 22610 (Workplace full of chemical or other fumes); 22611 (Workplace had a
178 lot of cigarette smoke from other people smoking); 22612 (Worked with materials
179 containing asbestos); 22613 (Worked with paints, thinners or glues); 22614 (Worked
180 with pesticides); and 22615 (Workplace had a lot of diesel exhaust).

181

182 Statistical Analyses

183

184 We used R 3.6.1¹⁸ to carry out analyses and generate plots, unless stated otherwise. For
185 the observational analyses, we removed prevalent cases and regressed the exposures
186 (i.e. BMI, BFP, WC, HC, and WHR) against prostate and breast cancer cases using a
187 logistic regression adjusting for age at baseline. We then generated genetic risk scores
188 (GRS) for the exposures in PLINK 1.9¹⁹ using sex-specific summary statistics from
189 GIANT^{14, 15} and Lu *et al.*¹¹ We tested the association between the GRSs and prostate and
190 breast cancer adjusting for the first four principal components (PCs) for the genetic
191 variability of the genome, age at baseline, and genotyping array used. We stratified the
192 sample by menopause and by chemical exposure and repeated this analysis. We used
193 the GRSs as instruments to carry out MR as described elsewhere.²⁰ We adjusted for the
194 first four genetic PCs and the genotyping array used in the first step and adjusted for
195 age at baseline in the second step.

196
197 Two-sample MR and multivariate MR analyses were carried out using the
198 TwoSampleMR R package.²¹ All of the independent loci used as instruments in the two-
199 sample MR analyses were based on sex-stratified GWAS meta-analyses of European
200 ancestry. For BFP, we used the sex-stratified summary statistics for 10 variants obtained
201 from Lu *et al.*¹¹ We obtained sex-stratified summary statistics from GIANT for waist-to-
202 hip ratio, waist circumference, hip circumference,¹⁴ and BMI.¹⁵ If a variant did not reach
203 genome-wide statistical significance for men or women in the sex-stratified analyses in
204 the external data, it was excluded. We used the same information for the multivariate
205 two-sample MR with the exception of BFP sex-stratified summary statistics, which were
206 not available, and the estimates were generated using UKB data instead. The outcome
207 data used were from Michailidou *et al.*¹² and Shumacher *et al.*,¹³ which are the meta-
208 analysis of breast cancer (122,977 cases, 105,974 controls) and the meta-analysis of
209 prostate cancer (79,194 cases, 61,112 controls), respectively.

210
211 To identify the potential confounders, we developed an algorithm that used a step-wise
212 procedure to identify any variables in the UKB that may be responsible for the observed
213 positive association between BMI and incident breast cancer cases. Only variables with
214 more than 1000 non-missing observations associated with both BMI and breast cancer
215 ($p < 0.05$) were considered. Categorical phenotypes were converted to separate binary
216 variables. Our algorithm selected variables based on the extent to which they minimised
217 the effect size of BMI on breast cancer.

219 RESULTS

220

221 After QC, we had 151,940 males and 174,410 females remaining in the sample. Table 1
222 summarises their age, BMI at baseline, and lifetime smoking status.

223

224 We first sought to examine the observational effect of the adiposity measures (i.e. BMI,
225 BFP, WC, HC, and WHR) on the risk of breast and prostate cancer. We only used incident
226 cases to avoid a previous cancer diagnosis affecting any of the measures considered. We
227 found that, in our sample, each of the adiposity measures are associated with an
228 increased risk of breast cancer but a decreased risk of prostate cancer (Figure 1 &
229 Supplementary Table 1).

230

231 We generated GRSs for each of the adiposity measures, for males and females
232 separately, to use as instrumental variables (Supplementary Table 2). We regressed the
233 outcomes on each of these GRSs to determine whether males and females who are
234 genetically predisposed to increased adiposity are at a decreased or increased risk of
235 developing prostate or breast cancer, respectively. We found that, in our sample, a
236 genetic predisposition to increased BMI, WC, and HC is associated with a decreased risk
237 of breast cancer in women, and that a genetic predisposition to increased BMI and WC
238 is associated with a decreased risk of prostate cancer (Supplementary Figures 1-3 &
239 Supplementary Table 3).

240

241 We found that the associations between the GRSs for BMI, WC, and HC and breast
242 cancer were present even after adjusting for BMI, WC, and HC, respectively
243 (Supplementary Table 4). This suggests that these GRSs violate the exclusion restriction
244 assumption, i.e. the genetic instrument may affect the outcome independently of the
245 exposure, and the estimated causal effect may be biased. We addressed this issue by
246 confirming our one-sample MR results using the MR Egger method, which is robust even
247 when the exclusion restriction assumption is violated. We found that the GRS for BMI
248 was not associated with prostate cancer independently of BMI. However, the GRS for
249 WC was associated with prostate risk independently of WC (Supplementary Table 4), so
250 the estimate of the causal effect of WC on prostate cancer risk obtained in the UKB may
251 also be biased.

252

We obtained estimates (odds ratios, OR, per SD unit increase) of the causal effect of the adiposity measures on breast and prostate cancer using one-sample MR (Figures 2 & 3). We found that increased BMI and HC decreased the risk of breast cancer (OR 0.776 [95% CIs 0.661 to 0.91, $p = 1.79 \times 10^{-3}$] and OR 0.781 [95% CIs 0.649 to 0.94, $p = 9.02 \times 10^{-3}$], respectively), and increased WC, BFP, and BMI decreased the risk of prostate cancer (OR 0.602 [95% CIs 0.439 to 0.825, $p = 1.61 \times 10^{-3}$], OR 0.629 [95% CIs 0.414 to 0.956, $p = 0.0301$], and OR 0.695 [95% CIs 0.553 to 0.874, $p = 1.89 \times 10^{-3}$], respectively).

We sought to replicate our findings using external outcome summary statistics from meta-analyses of 122,977 breast cancer cases¹² and 79,194 prostate cancer cases,¹³ and external exposure summary statistics from Lu *et al.*¹¹ and GIANT.^{14, 15} We used two-sample MR to assess the causal effect of adiposity measures on breast and prostate cancer risk (Tables 2 & 3). We found that increased BMI, WC, HC, and BFP are causally protective for breast cancer using the inverse variance weighted method (Supplementary Figure 4). The p-values of the intercept from the MR Egger method suggest that the instruments used for BMI, WC, and HC may be pleiotropic, but the causal estimates generated using MR Egger show that increased BMI, WC, and HC are still protective for breast cancer when any bias from pleiotropy is taken into account (Table 2). We also found that BMI was the only adiposity measure causally protective for prostate cancer (Supplementary Figure 5).

We next performed multivariable MR to identify whether the protective effects of increased BMI, WC, HC, and BFP on breast cancer risk are independent of each other (Supplementary Table 6). We found that BMI and BFP were still protective for breast cancer independently of the other measures, but WC and HC were not.

We hypothesised that the protective effect of adiposity may be due to adipose tissue absorbing and safely storing environmental carcinogens. We, therefore, stratified our sample, based on self-reported exposure to dust and/or chemicals and/or fumes at work and repeated the analyses. We found that the protective effect of increasing adiposity on prostate cancer was stronger in men who reported that they were frequently exposed to potentially hazardous substances at work in comparison those who were not. This is particularly evident for BMI and WC, where the confidence

286 intervals of the frequently and infrequently exposed strata do not overlap (Figure 3). We
287 did not observe the same pattern in women (Figure 2).

288

289 We stratified women based on their menopause status at breast cancer diagnosis (or at
290 baseline for controls). We did not find evidence that the protective effect of adiposity
291 was different between pre- and post-menopausal women, with the estimates between
292 the groups being similar and having overlapping confidence intervals (Figure 2).

293

294 We used a stepwise procedure to identify any confounding variables that might explain
295 the opposite direction of effects estimated by the observational and MR associations of
296 BMI with risk of breast cancer. Supplementary Table 7 lists the fields that were both
297 associated with incident breast cancer risk and attenuated the detrimental effect of
298 BMI. The $\ln(\text{OR})$ of breast cancer per SD unit increase in BMI is reduced tenfold when
299 these variables (namely ankle spacing width, frequency of stair climbing, amount of
300 moderate physical activity, macular degeneration, and leukocyte count) are added to
301 the model, but it does not decrease below zero. It is possible that the variables our
302 algorithm selects may be associated with a missing or currently unknown higher order
303 variable that may explain the discrepancy between the observed and causal associations
304 between BMI and risk of breast cancer.

305

306 DISCUSSION

307

308 We sought to assess the causal effects of increased adiposity on the risk of breast and
 309 prostate cancer. We found that increased adiposity measures were observationally
 310 associated with a lower risk of prostate cancer, but with an increased risk of female
 311 breast cancer. When we assessed the causal effects of the adiposity measures on the
 312 risk of prostate and breast cancer using a one sample MR, we found that increased BMI,
 313 BFP, and WC were causally protective for prostate cancer, and increased BMI and HC
 314 were causally protective for breast cancer. Using a two sample MR with previously
 315 published data, BMI was further confirmed as causally protective for both outcomes,
 316 and HC was confirmed as causally protective for breast cancer. Multivariable MR
 317 analyses suggest that BFP and BMI are the independent drivers of these protective
 318 associations between the adiposity measures and breast cancer. When testing whether
 319 or not these protective effects could be attributed to the safe storage of chemicals in
 320 adipose tissue, we showed that the causally protective effect on prostate cancer was
 321 consistently stronger, though not always statistically significant, in those reporting
 322 exposure to potentially carcinogenic substances at work. However, no such association
 323 was evident for breast cancer. When we attempted to identify the confounders
 324 responsible for the observed detrimental association between increasing BMI and
 325 breast cancer, we found a number of variables that may be involved, but these are of a
 326 currently uncertain clinical significance.

327

328 In this work, we found that increases in all of the adiposity measures we tested were
 329 observationally associated with a higher number of breast cancer cases. In this respect,
 330 the UK Biobank is in agreement with a previously published large meta-analysis of 126
 331 studies finding the same association.²² The inverse associations between the adiposity
 332 measures and prostate cancer were more surprising. Here the evidence are more
 333 heterogeneous, as illustrated by a recent large scale meta-analysis,¹⁰ which found an
 334 overall null association between BMI and prostate cancer, but found an inverse
 335 association between BMI and prostate specific antigen concentrations. Furthermore, a
 336 number of well powered studies^{23, 24} have also identified an inverse association
 337 between BMI and prostate cancer, so our results in the UK Biobank are, therefore, not
 338 unusual. Furthermore, increased adiposity is only protective for low grade prostate
 339 cancer,¹⁰ the prostate cancer cases in the UKB are likely to be low grade due to the age

340 of the sample, and this may further explain why we found an inverse observational
 341 relationship between adiposity and prostate cancer risk.
 342
 343 Since observational studies cannot directly provide information on cause and effect
 344 relationships, we carried out MR analyses to see whether the associations we found
 345 were causal. We found that adiposity was causally protective for breast cancer and our
 346 results are similar to those reported by Guo *et al.*⁶ using the same study but with a
 347 lower number of cases. Observationally, adiposity has been reported to be protective
 348 for pre-menopausal breast cancer,⁹ but our results suggest that this protective effect
 349 can only be established for post-menopausal breast cancer cases, though the absence of
 350 a protective effect in pre-menopausal breast cancer cases may be due to the smaller
 351 number of cases in this cohort. We show that the causal estimate of the protective
 352 effect of body fat percentage on breast cancer is independent of the causal effect of
 353 BMI, and it is more reliable because we find no evidence that the GRS for BFP is
 354 pleiotropic. We also found evidence that the association between BMI and breast
 355 cancer is confounded, and that the confounder is likely to be either a non-observed
 356 variable or a higher order variable combining different existing variables in the data. We
 357 also found that BMI is causally protective for prostate cancer in the UK Biobank dataset,
 358 and this is supported by our analysis of external data. Davies *et al.*⁷ report no causal
 359 effect of BMI on prostate cancer, but this may be due to lack of statistical power
 360 because they used a smaller number of cases (20,848 vs. 79,194).
 361
 362 There is previously published evidence which suggests that adipose tissue may play a
 363 role in safely storing harmful chemicals.²⁵ Persistent organic pollutant (POP)
 364 concentrations increase by 2-4% per kg of weight loss and remain elevated for up to 12
 365 months after a weight loss intervention.²⁶ We hypothesised that the protective effect of
 366 increasing adiposity on prostate and breast cancer risk might be explained by its ability
 367 to sequester potentially carcinogenic substances. Our results, which show that the
 368 protective effect was enhanced in men reporting more frequent exposure to potentially
 369 carcinogenic substances at work, support our hypothesis in prostate cancer. The same
 370 effect was not observed in female breast cancer, which may be due to an insufficient
 371 number of cases or due to a more complex underlying mechanism.
 372

373 The direction of the observational association between BMI and breast cancer is
 374 opposite to that of the causal effect, which suggests that the former is confounded. We
 375 found that variables relating to physical activity (i.e. frequency of stair climbing and
 376 moderate physical activity) may be one source of confounding and this is supported by
 377 the fact that increased physical activity is protective for breast cancer²⁷. Our algorithm
 378 also selected macular degeneration (an eye disease for which increasing age is the
 379 strongest risk factor and circulating lipids have also been involved),²⁸ ankle width (which
 380 might represent swelling of the lower extremities – symptoms of diabetes and
 381 cardiovascular disease), and leukocyte count (a marker of systemic inflammation).²⁹
 382 These variables are likely to represent a currently undefined higher order variable,
 383 perhaps biological age or a marker of overall health, and further investigation is
 384 required to identify what this variable might be and whether or not it can be modified
 385 to minimise breast cancer risk.

386
 387 A number of limitations are present in our work. The UK Biobank study, despite its
 388 sample size and almost comprehensive phenotyping, does have a "healthy volunteer"
 389 selection bias. The rate of cancer is lower in comparison to the general population.³⁰
 390 Also, the proportion of adults who were overweight or obese among men and women in
 391 the UK population was 78% and 73%, respectively, compared to 74% and 60%,
 392 respectively, for the same age group in the UK Biobank.³¹ The sample is, therefore, not
 393 representative of adiposity in the wider UK population.

394
 395 In conclusion, we found that increased adiposity is causally protective for breast and
 396 prostate cancer and the effects in the prostate cancer, at least partly, may be due to the
 397 safe sequestration of chemicals in adipose cells. Further work needs to be done to
 398 identify variables that are responsible for the observed relationship between increased
 399 BMI and increased risk of breast cancer. It is clear that reduction of adiposity, in and of
 400 itself, may not reduce the risk of breast and prostate cancer as the recent campaign by
 401 Cancer Research UK³ might suggest. It is necessary to explore the mechanisms through
 402 which adiposity may protect against or be a risk factor for cancer, to identify how the
 403 latter can be minimised without sacrificing the former, and to base public health
 404 campaigns around sound evidence.

405

406 **ACKNOWLEDGEMENTS**

407

408 We would like to thank the UKB staff and the UKB participants.

409

410 **FUNDING**

411

412 The work was supported by a Brunel Research Initiative and Enterprise Fund. HAA is the
413 recipient of a PhD studentship from the College of Health and Life Sciences, Brunel
414 University London.

415

416 **DISCLOSURES**

417

418 The authors have no conflicts of interest to declare.

419

420 REFERENCES

421

- 422 1. Bray F, Ferlay J, Soerjomataram I et al. Global cancer statistics 2018: GLOBOCAN
423 estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA:
424 A Cancer Journal for Clinicians 2018; 68: 394-424. . doi:10.3322/caac.21492
- 425 2. Laudicella M, Walsh B, Burns E, Smith PC. Cost of care for cancer patients in England:
426 evidence from population-based patient-level data. British Journal of Cancer 2016;
427 114: 1286-1292. . doi:10.1038/bjc.2016.77
- 428 3. Cancer Research UK. Obesity, weight and cancer. 2019
- 429 4. Stone TW, McPherson M, Gail Darlington L. Obesity and Cancer: Existing and New
430 Hypotheses for a Causal Connection. EBioMedicine 2018; 30: 14-28. .
431 doi:10.1016/j.ebiom.2018.02.022
- 432 5. Gao C, Patel CJ, Michailidou K et al. Mendelian randomization study of adiposity-
433 related traits and risk of breast, ovarian, prostate, lung and colorectal cancer. Int J
434 Epidemiol 2016; 45: 896-908. . doi:10.1093/ije/dyw129
- 435 6. Guo Y, Andersen SW, Shu X et al. Genetically Predicted Body Mass Index and Breast
436 Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of
437 European Descent. PLOS Medicine 2016; 13: e1002105. .
438 doi:10.1371/journal.pmed.1002105
- 439 7. Davies NM, Gaunt TR, Lewis SJ et al. The effects of height and BMI on prostate cancer
440 incidence and mortality: a Mendelian randomization study in 20,848 cases and
441 20,214 controls from the PRACTICAL consortium. Cancer Causes Control 2015; 26:
442 1603-1616. . doi:10.1007/s10552-015-0654-9
- 443 8. Iyengar NM, Arthur R, Manson JE et al. Association of Body Fat and Risk of Breast
444 Cancer in Postmenopausal Women With Normal Body Mass Index: A Secondary
445 Analysis of a Randomized Clinical Trial and Observational Study. JAMA Oncol 2019;
446 5: 155-163. . doi:10.1001/jamaoncol.2018.5327
- 447 9. Schoemaker MJ, Nichols HB, Wright LB et al. Association of Body Mass Index and Age
448 With Subsequent Breast Cancer Risk in Premenopausal Women. JAMA Oncol 2018;
449 4: e181771. . doi:10.1001/jamaoncol.2018.1771
- 450 10. Harrison S, Tilling K, Turner EL et al. Systematic review and meta-analysis of the
451 associations between body mass index, prostate cancer, advanced prostate cancer,
452 and prostate-specific antigen. Cancer Causes Control 2020. doi:10.1007/s10552-
453 020-01291-3

- 454 11. Lu Y, Day FR, Gustafsson S et al. New loci for body fat percentage reveal link
455 between adiposity and cardiometabolic disease risk. *Nature Communications* 2016;
456 7: 1-15. . doi:10.1038/ncomms10495
- 457 12. Michailidou K, Lindström S, Dennis J et al. Association analysis identifies 65 new
458 breast cancer risk loci. *Nature* 2017; 551: 92-94. . doi:10.1038/nature24284
- 459 13. Schumacher FR, Olama AAA, Berndt SI et al. Association analyses of more than
460 140,000 men identify 63 new prostate cancer susceptibility loci. *Nature Genetics*
461 2018; 50: 928-936. . doi:10.1038/s41588-018-0142-8
- 462 14. Shungin D, Winkler TW, Croteau-Chonka DC et al. New genetic loci link adipose and
463 insulin biology to body fat distribution. *Nature* 2015; 518: 187-196. .
464 doi:10.1038/nature14132
- 465 15. Locke AE, Kahali B, Berndt SI et al. Genetic studies of body mass index yield new
466 insights for obesity biology. *Nature* 2015; 518: 197-206. . doi:10.1038/nature14177
- 467 16. Sudlow C, Gallacher J, Allen N et al. UK biobank: an open access resource for
468 identifying the causes of a wide range of complex diseases of middle and old age.
469 *PLoS Med* 2015; 12: e1001779. . doi:10.1371/journal.pmed.1001779
- 470 17. Clare Bycroft, Colin Freeman, Desislava Petkova et al. The UK Biobank resource with
471 deep phenotyping and genomic data. *Nature* 2018; 562: 203-3. .
472 doi:10.1038/s41586-018-0579-z
- 473 18. R Core Team. R: A language and environment for statistical
474 computing. <https://www.R-project.org/> 2019
- 475 19. Chang CC, Chow CC, Tellier LC et al. Second-generation PLINK: rising to the challenge
476 of larger and richer datasets. *Gigascience* 2015; 4: 7. . doi:10.1186/s13742-015-
477 0047-8
- 478 20. Burgess S, Small DS, Thompson SG. A review of instrumental variable estimators for
479 Mendelian randomization. *Stat Methods Med Res* 2017; 26: 2333-2355. .
480 doi:10.1177/0962280215597579
- 481 21. Hemani G, Zheng J, Elsworth B et al. The MR-Base platform supports systematic
482 causal inference across the human phenome. *Elife* 2018; 7.
483 doi:10.7554/eLife.34408
- 484 22. Chan DSM, Abar L, Cariolou M et al. World Cancer Research Fund International:
485 Continuous Update Project-systematic literature review and meta-analysis of
486 observational cohort studies on physical activity, sedentary behavior, adiposity, and
487 weight change and breast cancer risk. *Cancer Causes Control* 2019; 30: 1183-1200. .
488 doi:10.1007/s10552-019-01223-w

- 489 23. Perez-Cornago A, Appleby PN, Pischon T et al. Tall height and obesity are associated
490 with an increased risk of aggressive prostate cancer: results from the EPIC cohort
491 study. BMC Med 2017; 15: 115. . doi:10.1186/s12916-017-0876-7
- 492 24. Rao GA, Mann JR, Bottai M et al. Angiotensin receptor blockers and risk of prostate
493 cancer among United States veterans. J Clin Pharmacol 2013; 53: 773-778. .
494 doi:10.1002/jcph.98
- 495 25. Lee Y-, Kim K-, Jacobs DR, Lee D-. Persistent organic pollutants in adipose tissue
496 should be considered in obesity research. Obesity Reviews 2017; 18: 129-139. .
497 doi:10.1111/obr.12481
- 498 26. Jansen A, Lyche JL, Polder A et al. Increased blood levels of persistent organic
499 pollutants (POP) in obese individuals after weight loss—A review. Journal of
500 Toxicology and Environmental Health, Part B 2017; 20: 22-37. .
501 doi:10.1080/10937404.2016.1246391
- 502 27. Papadimitriou N, Dimou N, Tsilidis KK et al. Physical activity and risks of breast and
503 colorectal cancer: a Mendelian randomisation analysis. Nature Communications
504 2020; 11: 1-10. . doi:10.1038/s41467-020-14389-8
- 505 28. Lambert NG, ElShelmani H, Singh MK et al. Risk factors and biomarkers of age-
506 related macular degeneration. Prog Retin Eye Res 2016; 54: 64-102. .
507 doi:10.1016/j.preteyeres.2016.04.003
- 508 29. Chmielewski PP, Strzelec B. Elevated leukocyte count as a harbinger of systemic
509 inflammation, disease progression, and poor prognosis: a review. Folia Morphol
510 (Warsz) 2018; 77: 171-178. . doi:10.5603/FM.a2017.0101
- 511 30. Office for National Statistics. Cancer registration statistics, England: 2017. 2019
- 512 31. NHS Digital. Statistics on Obesity, Physical Activity and Diet, England, 2019. 2019
- 513

FIGURES

515

Figure 1

517 Odds ratios per SD increase (OR) and 95% confidence intervals when regressing incident
518 breast and prostate cancer cases on the adiposity measures using a logistic regression.
519 BMI = body mass index. BFP = body fat percentage. HC = hip circumference. WC = waist
520 circumference. WHR = waist-to-hip ratio.

521

522

523

524

Figure 2

Odds ratios (OR) and 95% confidence intervals from a one-sample MR analysis of the causal effect of adiposity on breast cancer risk. BMI = body mass index. BFP = body fat percentage. HC = hip circumference. WC = waist circumference. WHR = waist-to-hip ratio.

534 Figure 3

535 Odds ratios (OR) and 95% confidence intervals from a one-sample MR analysis of the
536 causal effect of adiposity on prostate cancer risk. BMI = body mass index. BFP = body fat
537 percentage. HC = hip circumference. WC = waist circumference. WHR = waist-to-hip
538 ratio.

539

540

541

542

543 **TABLES**

544

545 Table 1

546 Population characteristics. SD = standard deviation.

547

Table 1

	males			females		
	all	controls	cases	all	controls	cases
n	151940	145227	6713	174410	164974	9436
age (SD), years	57.1 (8.08)	56.8 (8.1)	63 (4.88)	56.6 (7.9)	56.5 (7.92)	58.9 (7.1)
BMI (SD), kg/m ²	27.8 (4.22)	27.8 (4.24)	27.6 (3.83)	27 (5.14)	27 (5.15)	27.3 (4.93)
% ever smoked	65.1	65	66.1	55.7	55.6	57.8

548

549

550 Table 2

551 Odds ratios (OR) and 95% confidence intervals from a two-sample MR analysis of the
 552 causal effect of adiposity on breast cancer risk in women. U 95% CI = upper 95%
 553 confidence interval. L 95% CI = lower 95% confidence interval. $P^{(\text{intercept})}$ = p-value of the
 554 intercept from the MR Egger method. BMI = body mass index. BFP = body fat
 555 percentage. HC = hip circumference. WC = waist circumference. WHR = waist-to-hip
 556 ratio.
 557

Table 2

Cancer	Exposure	Method	<i>P</i>	OR	L 95% CI	U 95% CI	$P^{(\text{intercept})}$
Breast	BMI	MR Egger	2.32E-05	0.444	0.321	0.616	0.00839
Breast	BMI	Inverse variance weighted	3.63E-08	0.683	0.596	0.782	NA
Breast	BFP	MR Egger	0.221	0.467	0.152	1.44	0.59
Breast	BFP	Inverse variance weighted	0.0215	0.63	0.425	0.934	NA
Breast	HC	MR Egger	0.00414	0.276	0.129	0.587	0.0236
Breast	HC	Inverse variance weighted	0.00725	0.689	0.525	0.904	NA
Breast	WC	MR Egger	3.64E-05	0.291	0.192	0.443	0.00124
Breast	WC	Inverse variance weighted	2.71E-05	0.643	0.523	0.79	NA
Breast	WHR	MR Egger	0.631	0.7	0.168	2.91	0.747
Breast	WHR	Inverse variance weighted	0.112	0.807	0.62	1.05	NA

558

559

560 Table 3

561 Odds ratios (OR) and 95% confidence intervals from a two-sample MR analysis of the
562 causal effect of adiposity on prostate cancer risk. U 95% CI = upper 95% confidence
563 interval. L 95% CI = lower 95% confidence interval. $P^{(\text{intercept})}$ = p-value of the intercept
564 from the MR Egger method. BMI = body mass index. BFP = body fat percentage. HC =
565 hip circumference. WC = waist circumference. WHR = waist-to-hip ratio.

566

Table 3

Cancer	Exposure	Method	OR	L 95% CI	U 95% CI	P	$P^{(\text{intercept})}$
Prostate	BMI	MR Egger	0.841	0.623	1.13	0.266	0.828
Prostate	BMI	Inverse variance weighted	0.815	0.73	0.91	0.000278	NA
Prostate	BFP	MR Egger	1.01	0.291	3.53	0.985	0.882
Prostate	BFP	Inverse variance weighted	0.921	0.696	1.22	0.563	NA
Prostate	HC	MR Egger	0.703	0.248	2	0.522	0.706
Prostate	HC	Inverse variance weighted	0.858	0.661	1.11	0.252	NA
Prostate	WC	MR Egger	1.39	0.203	9.53	0.745	0.664
Prostate	WC	Inverse variance weighted	0.801	0.604	1.06	0.123	NA
Prostate	WHR	MR Egger	0.482	0.183	1.27	0.277	0.23
Prostate	WHR	Inverse variance weighted	0.842	0.659	1.08	0.17	NA

567

568